revenues grew a decent 13% year-on-year (y-o-y). Its stock gained about 8% on the better-than-expected Q2 performance.Cadila’s divisions have all perked up nicely with US growing at about 18% y-o-y.
The India business growth of 11% is good given that the acute segment is not firing that well. The increased demand for active pharma ingredients (API) also pushed revenues in this division higher by about 52%.In the coming quarters, investors are banking on the increased contribution from the covid-19 portfolio.
The firm is working on a covid-19 vaccine with immunogenicity and efficacy data likely to be out soon. Besides, backward integration in API manufacturing is aiding margins in its covid-19 portfolio.“Cadila has launched the most.